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Abstract 1 
Collagen prolyl hydroxylation (CPH), which is catalyzed by prolyl 4-hydroxylase (P4H), is the 2 
most prevalent posttranslational modification in humans and requires Vitamin C (VitC). Here we 3 
demonstrate that CPH acts as an epigenetic modulator of cell plasticity. Increased CPH induced 4 
global DNA/histone methylation in pluripotent stem and tumor cells and promoted cell state 5 
transition (CST). Interfering with CPH by either genetic ablation of P4H subunit alpha-2 6 
(P4HA2) or pharmacologic treatment reverted epigenetic changes and antagonized CST. 7 
Mechanistically, we suggest that CPH modifies the epigenetic landscape by reducing VitC for 8 
DNA and histone demethylases. Repurposed drugs targeting CPH-mediated metabolic 9 
perturbation, such as the antiasthmatic Budesonide, blocked metastatic dissemination of breast 10 
cancer cells in vivo by preventing mesenchymal transition. Our study provides mechanistic 11 
insights into how metabolic cues and epigenetic factors integrate to control cell state transition 12 
and paves the way for the development of novel antimetastatic strategies 13 
 14 
Significance: A phenotype-based HTS reveals unforeseen metabolic control of cell plasticity and 15 
identifies Budesonide as a drug candidate for metastatic cancer 16 
 17 
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 3 
Introduction 1 
Cell plasticity is the ability of cells to switch between different phenotypic states in a reversible 2 
manner. Besides its crucial role in the development of multicellular organisms and tissue 3 
homeostasis, cell plasticity contributes to the progression of devastating pathologies, including 4 
metastatic cancer and organ fibrosis (1-3). The primary source of cell plasticity is the Epithelial-5 
Mesenchymal Transition (EMT). EMT is not an all-or-none, irreversible process, as cohesive 6 
epithelial cells and free motile/migrating mesenchymal cells represent only the extreme of a 7 
continuum of intermediate/metastable phenotypes. How cell state transition is controlled and 8 
what are the molecular determinants that enable cells to reside stably in one or another 9 
phenotypic state is a major unresolved issue (2, 4). Transient metabolic perturbations that modify 10 
the availability of epigenetic enzymes required metabolites (EEMs) are emerging as candidate 11 
determinants of cell plasticity (5). Typical examples are the ascorbic acid [Vitamin C (VitC)] and 12 
the alpha-ketoglutarate (KG) that are cofactors/enhancers for the Fe+2/KG -dependent 13 
dioxygenases superfamily (6), which include the Ten-Eleven Translocation (TET) DNA 14 
demethylases and the Jumonji (JMJ) domain–containing histone demethylases. VitC, for 15 
instance, by enhancing the activity of the TET and JMJ demethylases, improves the efficiency of 16 
induced pluripotent stem cell (iPSC) generation (7-10), drives embryonic stem cells (ESCs) 17 
towards a naive state of pluripotency (11, 12) and regulates the balance between self-renewal and 18 
differentiation of hematopoietic stem cells (13, 14). Thus, fluctuation of EEMs’ concentrations is 19 
considered an additional layer of epigenetic regulation (15). Yet, how this is regulated is still 20 
unknown. Here, we reveal that VitC -consuming collagen prolyl hydroxylases (P4Hs), which 21 
catalyze the hydroxylation of prolyl residues on nascent collagens, are key players in this 22 
complex regulatory scenario. Specifically, through an unbiased phenotype-based screening of 23 
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 4 
1.200 FDA-approved drugs, we identify compounds that are used to gain insight into unexplored 1 
molecular mechanisms of cell plasticity, and as drugs to target diseases associated with cell state 2 
transition, most and foremost cancer progression and metastatic dissemination. 3 
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Materials and Methods 1 
Cell lines, culture conditions and treatments 2 
SUM159 cells were from Asterand (2015), and A549 cells were from NIH NCI-60 cell line panel 3 
(2011) and their identity and mycoplasma free-state is routinely (annually) tested by DNA 4 
fingerprinting using Short tandem repeat (STR) profiling, and by PCR-based, MycoAlertTM 5 
Mycoplasma Detection Kit (Lonza, Bioscience). Each cell lines were used within passage 4/5 6 
since their thawing from originally frozen vials. 7 
A549 cells were cultured in high glucose DMEM (Invitrogen, Life Technologies), 10% FBS 8 
(Euroclone), 2 mM glutamine and penicillin/streptomycin (100 U/ml, GIBCO). SUM-159 cells 9 
were cultured in F12 medium with inactivated calf serum (5%), 10 mM Hepes, 1 ug/ml 10 
hydrocortisone (HYC), insulin (5ug/ml), and penicillin/streptomycin. For quantification of 11 
collagen and Collagen-Hydroxyproline (C-HyP), and histone methylation, WT SUM159 cells 12 
were starved of HYC for 48hrs and then treated with HYC ± Budesonide (25M) for 48 hours.  13 
Wild-type TBV2 (129/SvP) were kindly provided by Dr. Stefania Filosa in 2008, P4ha2KO and 14 
P4ha2
KO/P4ha1KD TBV2 mouse ESCs were maintained as reported (16); mycoplasma free-state 15 
is routinely (twice/year) tested by PCR-based assay. All the experiments were performed 16 
between the 5th and the 20th cell passage. 17 
L-Pro-induced esMT was performed as described (16). Briefly, ESCs (250 cells/cm2) were plated 18 
onto gelatin-coated plates in ESC medium (DMEM/10%FBS/LIF) ± L-Pro (500 μM - 1 mM) for 19 
5 days. Medium was renewed at day 3 with addition of fresh L-Pro.  20 
PiC to ESC reverse transition (MesT) was performed as described (16). VitC (Sigma-Aldrich) 21 
was dissolved in water. CHIR99021 was dissolved in DMSO and used at 3 μM (Millipore). 22 
on May 18, 2019. © 2019 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on May 6, 2019; DOI: 10.1158/0008-5472.CAN-18-2070 
 6 
EsMT inhibitors (Sigma-Aldrich) were dissolved in DMSO at 10 mM and used at concentration 1 
ranging from 5 to 20 μM. 2 
The Alkaline phosphatase (AP) assay was performed using AP staining kit (System Biosciences) 3 
following manufacturer’s instructions. 4 
For Collagen and C-HyP quantification, ESCs (15x103/cm2) or PiCs (15x103/cm2) were plated 5 
in gelatin and treated ± L-Pro and ± Budesonide and VitC. After 48hrs in culture, cells were 6 
collected and analyzed either by WB or immunofluorescence (see below for details).  7 
 8 
High-throughput screening 9 
The Prestwick Chemical Library® 1200 compounds (ww.prestwickchemical.com/libraries-10 
screening-lib-pcl.html) was used for the screening. The screening was performed using the 11 
Cell
maker
 robotic platform (16). TBV2 ESCs were plated at 250 cells/cm2 in gelatin-coated plates 12 
(96-multiwell) in DMEM/10%FBS/LIF. Five hours after plating, cells were supplemented with 13 
L-Pro (250 µM) or left untreated as control, and the compounds (Prestwick chemical library®) 14 
were singularly added at a final concentration of 10 µM. At day 4 after treatment, the resulted 15 
colonies were fixed/stained in PBS1x/6% glutaraldehyde/0.15% crystal violet for 30 min at RT. 16 
The plates were scanned/imaged and the cell colonies (if any) were analyzed using the ImageJ 17 
1.46r software (http://image.nih.gov/ij). 18 
Chemical structure information for Budesonide are available at [Pubchem 19 
(https://pubchem.ncbi.nlm.nih.gov/compound/5281004),DrugBank(https://www.drugbank.ca/dru20 
gs/DB01222) and Therapeutic Target Database (https://db.idrblab.org/ttd/drug/d0y7iu). 21 
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 7 
RNA extraction and quantitative RT-PCR 1 
Total RNAs were extracted using the RNeasy kit (Quiagen) and reverse transcribed with the 2 
QuantiTect Reverse Transcription kit (Qiagen). qPCR was performed using SYBR Green PCR 3 
master mix (FluoCycle IITM SYBR, EuroClone). Primers are listed in Table S1. 4 
 5 
Cell proliferation assays 6 
Cell proliferation was evaluated using FACS- based EdU incorporation (Click-iT® EdU Flow 7 
Cytometry Assay kit; Molecular Probes), and the CCK-8 (Dojindo Laboratories, Kumamoto, 8 
Japan) assays following manufacturer instructions.  9 
 10 
Western blot 11 
Total proteins were extracted in 100 mM Tris pH 8, 140 mM NaCl, 20 mM EDTA, 0,2% SDS, 12 
1% Nonidet P-40 lysis buffer, resolved on SDS-PAGE gels and transferred onto PVDF 13 
membranes (iBlot dry Transfer System; Life Technologies).  14 
Histones proteins were prepared as follows: cell pellets were resuspended  in Triton Extraction 15 
Buffer (TEB: PBS containing 0.5% Triton X 100 (v/v), 2mM phenylmethylsulfonylfluoride 16 
(PMSF), 0.02% (w/v) NaN3 ) at a cell density of 107 cells per ml. Then, the pellets were lysed 17 
overnight in 0,2N HCl at a density of 4x107 cells/ml. 18 
Primary Antibodies (listed in Table S2) were used overnight at 4°C followed by the appropriate 19 
HRP-conjugated secondary antibodies. Detection was performed with ECL reagents (Pierce, 20 
Thermo Scientific). ImageJ software was used for the densitometric analysis. 21 
 22 
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 8 
Immunofluorescence analysis and quantification 1 
Cells were fixed (4% PFA) and permeabilized (0.1% Triton X-100) for 10 minutes at RT and 2 
incubated with blocking solution (0.1% Triton X-100/5% BSA) for 1 hrs. Primary Antibodies 3 
(listed in Table S2) were incubated overnight (4°C) followed by the relative secondary 4 
antibodies (Alexa Fluor Molecular Probes) 5 
Images were obtained using the DMI6000B microscope equipped with DFC 350FX B/W digital 6 
camera (Leica Microsystems). Confocal images were obtained on a Nikon A1 microscope. The 7 
AF6000 (Leica Microsystems) and NIS Element C (Nikon, Tokyo) software were used for image 8 
acquisition/elaboration. 9 
For cytospin samples, dissociated cells were resuspended in 15% FBS/1x PBS and centrifuged at 10 
800 rpm for 8 min using a Thermo Shandon Cytocentrifuge (CytoSpinTM 4), and fixed for 11 
further analysis. 12 
C-HyP positive area (pixel/cm2) was measured over the total nuclei area (100-300 13 
cells/conditions) using ImageJ software ( https://imagej.nih.gov/ij/docs/guide/146-30.html#toc-14 
Subsection-30.2)  15 
 16 
Generation of P4ha2KO and P4ha2KO/P4ha1KD ESCs and tumor cells 17 
For CRISPR/Cas9 mediated P4ha2 knock-out, TBV2 ESCs were infected with lentiviral 18 
particles (1 MOI) carrying the guide RNA (gRNA), which targets P4ha2 exon 6 19 
(ATCCGGACACGATTTCCAGA) followed by the Cas9 and the Puromycin resistance 20 
[transEDIT™ Lentiviral gRNA plus Cas9 (pCLIP-All) Target Gene; transOMIC technologies]. 21 
Following Puromycin selection (1 µg/ml; 6 days), resistant cells were dissociated and single cells 22 
were FACS-sorted (FACS Aria, Becton Dickinson) on the basis of FSC/SSC parameters and 23 
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seeded into 96-well plates. Genomic DNA was analyzed by PCR using primers designed on 1 
intron 5-6 (forward) and 6-7 (reverse) sequences that amplify a product of 735 bp. IN/DEL 2 
mutations were identified by digesting PCR products with the T7 endonuclease and confirmed 3 
by sequencing. The absence of the wild type allele was confirmed by RT-PCR (see Table S1). 4 
P4ha2
KO/P4ha1KD ESCs were obtained by transfecting P4ha2KO ESCs (Clone #1) with short 5 
hairpin RNAs (shRNAs) plasmids targeting different non-overlapping P4ha1 mRNA sequences 6 
followed by a GFP reporter (shERWOOD UltramiR Lentiviral shRNA, pZIP-mEF1a, 7 
TransOMIC). 48hrs after electroporation single GFP positive cells were FACS sorted into 96-8 
well plates, and analyzed as above. 9 
Stable P4HA2KD A549 and SUM159 cells were generated by lentiviral infection of shRNAs 10 
(PLKO, SIGMA) followed by Puromycin selection (1 µg/ml; 10 days).  11 
 12 
Quantification of 5hmC  13 
Gelatin plated ESCs (15x103/cm2) were pre-treated with VitC (50 µM; 24 hrs) before addition of 14 
L-Pro ± Budesonide for 24 hrs. For ELISA- based quantification, genomic DNA was extracted 15 
(WizardR Genomic DNA Purification kit; Promega) and 5hmC levels were measured using 16 
MethylFlashTM Global DNA Hydroxymethylation (5hmC) ELISA Easy Kit (Epigentek) and 17 
normalized to DNA content, following the manufacturer instructions.  18 
For immunofluorescence, cells were fixed (4% PFA) and permeabilized (0.4% Triton X-100; 19 
15min at RT). After a denaturation step (2N HCl, 15min at RT) and a neutralization step (100 20 
mM Tris-HCl pH 8.5, 10min at RT), cells were incubated with 0.1% Triton X-100/5% BSA for 1 21 
hr. Anti 5-hmC monoclonal Antibody was incubated overnight at 4°C (1:200, HMC/4D9 A1018, 22 
Epigentek) followed by anti-mouse 594 secondary antibody (Alexa Fluor Molecular Probes). 23 
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 10 
Images were obtained using the DM6000B microscope equipped with DFC 350FX B/W digital 1 
camera (Leica Microsystems). The AF6000 (Leica Microsystems) software was used for image 2 
acquisition/elaboration. 3 
 4 
DNA methylation data analysis 5 
DNA methylation comparison between L-Pro treated- and Tet TKO mESCs was performed as 6 
described (17). Briefly, the Tet TKO hyper-DMRs (18) in which at least 3 CpGs were covered by 7 
L-Pro RRBS experiments (6) were selected for the analysis. For each region, the ratio between 8 
the number of hypermethylated CpGs ((L-Pro vs VitC)≥20%) and total CpGs was calculated. DMRs 9 
with a ratio greater than 0.3 were defined hypermethylated. The statistical significance of 10 
enrichment was determined using the one tail hypergeometric test available in R. 11 
 12 
Time-Lapse  13 
Images from ESCs ± L-Pro (500 µM) ± esMTi and A459 tumor spheroids ± Budesonide were 14 
captured (20x) at the indicated time point, every 5 min for about 24 hrs on a Leica DMI6000B 15 
equipped with a microscope incubator (Okolab). 16 
 17 
2D migration assays  18 
Boyden chamber assay was performed using polycarbonate transwells (8 μm pore, Costar). 19 
Briefly, A549 cells pre-treated ± Budesonide or DMSO in complete medium. After 24 hrs, cells 20 
were dissociated by trypsin-EDTA, seeded (4*105 cells/per insert) in DMEM/1% FBS ± 21 
Budesonide and allowed to migrate towards FBS gradient (1%-15%) for 6 hrs. Nuclei were 22 
stained and migrated cells were counted (4 random fields/insert, 10x). 23 
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For A549 tumor spheroid assay, 2.5 x103 FACS sorted cells were plated/well in V-shaped low 1 
attachment 96-multiwell (Corning Costar) and allowed to aggregate for 4 days. Spheroids were 2 
plated on gelatin-coated wells in complete medium without growth factors. After 48 hrs, tumor 3 
spheroids were fixed and stained (PBS1x/6% glutaraldehyde/0.15% crystal violet) for 30min at 4 
RT. The percentage of spreading spheroids was determined by quantifying the number of 5 
spheroids with a crown of mesenchymal/migrating cells over the total number of spheroids 6 
plated. 7 
 8 
3D Organotypic culture 9 
For the analysis of SUM-159-derived spheroids invasive outgrowth, single SUM-159 cells were 10 
plated in 8-well chamber slides (IBIDI) onto a base layer of Matrigel and collagen I (5 mg/ml 11 
and 2.3 mg/ml, respectively; BD) and supplemented with a 2% Matrigel/growth medium 12 
mixture. Cultures were grown for 6 days. Medium was replenished every 2 days. SUM-159 13 
spheroids were imaged for development of invasive outgrowths by differential interference 14 
contrast (DIC) imaging using a 20X objective lens. Colonies circularity and area parameters 15 
were calculated using ImageJ software. 16 
 17 
Xenograft experiments 18 
All animal experiments were approved by the OPBA (Organisms for the well-being of the 19 
animal) of IFOM and Cogentech. All experiments complied with national guidelines and 20 
legislation for animal experimentation. All mice were bred and maintained under specific 21 
pathogen-free conditions in our animal facilities at Cogentech Consortium at the FIRC Institute 22 
of Molecular Oncology Foundation and at the European Institute of Oncology in Milan, under 23 
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the authorization from the Italian Ministry of Health (Autorizzazione N° 604-2016). SUM-159 1 
cells, expressing pLenti CMV-Puro-LUC construct (Plasmid #17477, ADDGENE), were trypsin 2 
detached, washed twice, and resuspended in PBS to a final concentration of 2.5*106 cells/13 μl. 3 
The cell suspension was then mixed with 5 μl growth factor–reduced Matrigel (BD) and 2 μl 4 
Trypan blue solution and maintained on ice until injection. Aseptic conditions under a laminar 5 
flow hood were used throughout the surgical procedure. Female NOD.Cg-6 
PrkdcscidIl2rgtm1Wjl/SzJ (commonly known as the NOD SCID gamma; NSG) mice (6–9 week 7 
old) were anesthetized with 375 mg/Kg Avertin, laid on their backs, and injected with a 20 μl 8 
cell suspension directly in the fourth mammary fad pad. After 4 days, mice were administered by 9 
intraperitoneal injection (I.P.) either Budesonide (3 mg/Kg) or the same volume of carrier as 10 
control, every day for 3 consecutive weeks. For bioluminescence imaging, 100 l of D-Luciferin 11 
(30 mg/ml, Perkin Elmer) was injected I.P. before placing mice under 2% inhaled isofluorane 12 
anesthesia. Bioluminescence signal was monitored every 5 days by measuring photon flux (15 13 
min from I.P. injection) using IVIS LUMINA III imaging System (Perkin Elmer).  Data were 14 
analyzed using average counts in the ROIs and normalized to acquisition time. At the endpoint, 15 
mice were sacrificed and tumors were harvested. Tumor volume was measured with digital 16 
caliper and calculated according to the formula: L x W2/2 = mm3. For histological analysis, 17 
primary tumors and lung metastases were fixed in 4% phosphate-buffered formalin and paraffin-18 
embedded. The Scan Scope XT device and the Aperio Digital pathology system software 19 
(Aperio) were used to collect pictures and detect metastases. 20 
 21 
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Immunohistochemistry 1 
Formalin-fixed, paraffin-embedded (FFPE) mouse tumor tissue and lungs sections (3 μm) were 2 
incubated with 3% H2O2 for 5 min and then blocked with 2% goat serum in PBS for 1 hr. 3 
Samples were incubated with primary antibodies (listed in Table S2) for 2 hrs at RT in 2% goat 4 
serum. HRP-conjugated secondary antibodies were used and signals were developed with DAB. 5 
Samples were counterstained with hematoxylin (Merck) or stained with Picrosirius Red 6 
(Polysciences Inc.). Cell circularity (stained with anti Vimentin) and collagen fiber distribution 7 
(observed in polarized light microscopy images) parameters were calculated using ImageJ 8 
software. 9 
 10 
Bioinformatic analysis of PH4A2 in cancer cohorts  11 
Survival analysis was performed exploiting the METABRIC breast cancer dataset (19), 12 
downloaded from the TCGA database. Expression data were extracted from the dataset (1980 13 
Breast Cancer samples) and three Illumina probesets were available for P4HA2; 14 
ILMN_1795778, ILMN_2381697, ILMN_2280135. mRNA expression data from the three 15 
probesets for each sample were averaged and samples were grouped into Low and High P4HA2 16 
expression based on the mRNA levels with respect to the mean. Data analysis was performed 17 
using JMP 10.0 statistical software (SAS Institute, Inc);  18 
 19 
Statistical analysis 20 
Statistical significance was determined by a two-tailed paired Student’s t-test. p-values ≤0.05 21 
were considered as statistically significant. Error bars represent SEM or SD as indicated. 22 
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Results 1 
High-throughput screen identifies inhibitors of embryonic stem to mesenchymal-like 2 
transition (esMT)  3 
We exploited the highly dynamic embryonic stem to mesenchymal-like transition (esMT) as a 4 
molecular and functional paradigm for reversible cell state transition (20, 21). To search for 5 
compounds able to block esMT we developed a fully automated unbiased high-throughput 6 
screening (HTS) in a 96-well format based on a robust cell colony phenotype assay (CFA) (Fig. 7 
1A and B). The CFA was optimized to achieve a high colony forming efficiency (72±9 8 
colonies/well) and high efficiency of domed-to-flat transition (Fig. 1A) after L-Pro 9 
supplementation (85±7% flat vs 12±6% domed colonies) (Fig. 1C; Supplementary Fig. S1A). 10 
The feasibility of the assay was verified using two potent esMT antagonists, i.e. L-Ascorbic acid 11 
(Vitamin C, VitC) and the GSK3 inhibitor CHIR99021 (16, 20), which robustly reduced the 12 
fraction of flat-shaped colonies to Control levels (~90% domed vs ~10% flat colonies) (Fig. 1C; 13 
Supplementary Fig. S1A). We employed this automated CFA to screen a Prestwick chemical 14 
library® containing 1.200 FDA-approved small molecules. ESCs were plated in the presence of 15 
L-Pro and exposed to either drugs or solvent (DMSO). At day four after plating, colonies were 16 
fixed and stained with a glutaraldehyde/crystal violet mix and subjected to phenotypic analysis 17 
(Fig. 1D). A substantial number of the drugs uniformly distributed throughout the plates (137, 18 
11.4%) completely inhibited cell colony formation (Table S3). In depth analysis of these ESC 19 
inhibitors (ESCi) revealed that: i) the large majority (80%) have anticancer activities (Table S4); 20 
ii) ~50% belongs to 5 therapeutic classes of the 135 covered by the library (Fig. 1E and F); and 21 
iii) their activities rely on specific structural constraints (Fig. 1G; Supplementary Fig. S1B and 22 
S1C). We next restricted the analysis to the drugs able to inhibit esMT, i.e. to significantly 23 
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 15 
reduce the fraction of L-Pro-induced atypical/flat colonies and increase the fraction of 1 
round/domed-shaped colonies. Fourteen esMT inhibitors [(esMTi) 1.2%; Table S5] were 2 
selected and validated in secondary CFAs (Fig. 1H; Supplementary Fig. S1D). Consistent with 3 
their antagonistic effect on esMT, the three most active drugs, Budesonide, Spiramycin and 4 
Propafenone (Supplementary Fig. S1E) prevented cell motility and induction of esMT markers 5 
(Fig. 2A; Supplementary Fig. S2A). Notably, Budesonide, Spiramycin and Propafenone 6 
prevented neither L-Pro induced down-regulation of Aminoacid stress response (AAR) pathway 7 
markers (Fig. 2B) nor cell proliferation (Fig. 2C), which are the earliest ESC responses to L-Pro 8 
supplementation and depend on L-Pro -tRNA loading (21). Finally, we tested their ability to 9 
promote the reversal mesenchymal-like-to-embryonic-stem-cell transition [MesT; (20)]. To this 10 
end, L-Pro-induced mesenchymal-like cells (PiCs) were plated at low density and treated with L-11 
Pro ± esMTi or VitC as control (Fig. 2D). Cells reverted back to the ESC phenotype in the 12 
presence of esMTi, with efficiency comparable to that observed for VitC (Fig. 2D). These results 13 
indicate that esMTi specifically block esMT acting downstream of L-Pro -tRNA loading, and 14 
induce MesT even in a highly rich L-Pro environment.  15 
 16 
Collagen accumulation underpins esMT  17 
To obtain mechanistic insights into esMT, we classified the 14 esMTi identified in the screening 18 
on the basis of their chemical properties. Despite belonging to 9 different classes (Tanimoto 19 
coefficient T>0.75) (Supplementary Fig. S2B), nearly 50% of the esMTi, including Budesonide, 20 
are inhibitors of collagen accumulation/fibrosis in vitro and/or in vivo (Table S6), pointing to a 21 
link between collagen accumulation and esMT. Notably, we recently showed that L-Pro -induced 22 
esMT depends on protein synthesis and that ESCs are specifically and intrinsically starved of L-23 
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Pro (21). Based on our findings and these considerations, and given that L-Pro and 4-trans-1 
hydroxyproline (HyP) are the major components of collagen, we hypothesized that L-Pro 2 
supplementation would increase collagen synthesis/hydroxylation in ESCs, eventually inducing 3 
esMT. Accordingly, Collagen (Col1a1) and collagen hydroxyproline (C-Hyp) levels both 4 
increased in L-Pro treated ESCs, accumulating primarily in the endoplasmic reticulum (ER; Fig. 5 
2 E and F; Supplementary Fig. S2C). Conversely, the esMTi Budesonide prevented Col1a1 6 
expression at RNA and protein levels, as well as C-Hyp in L-Pro-treated cells (Fig 2G-J; 7 
Supplementary Fig. S2D). Budesonide is a 21-hydroxysteroid glucocorticoid; however, none of 8 
the other twenty-four 21-hydroxysteroids derivatives, including the glucocorticoid 9 
Dexamethasone, was identified as a positive hit in the primary screening (Supplementary Fig. 10 
S2E) and confirmed in the secondary CFA (Supplementary Fig. S2F), thus revealing a highly 11 
specific effect of Budesonide. Of note, among the 25 21-hydroxysteroids included in the library, 12 
only Budesonide is classified as a high-affinity Glucocorticoid Receptor (GR) antagonist in 13 
different databases, including [Pubchem 14 
(https://pubchem.ncbi.nlm.nih.gov/compound/5281004), DrugBank 15 
(https://www.drugbank.ca/drugs/DB01222) and Therapeutic Target Database 16 
(https://db.idrblab.org/ttd/drug/d0y7iu). This raised the possibility that Budesonide specificity 17 
might be due, at least in part, to its activity as GR antagonist. Interestingly, addition of another 18 
established antagonist of GR, Mifepristone, was able to block esMT similarly to Budesonide 19 
(Supplementary Fig. S2F). Furthermore, Budesonide but not Dexamethasone reduced the levels 20 
of the well known GR target Alkaline Phosphatase (22), while keeping ESC undifferentiated 21 
(Supplementary Fig. S2G). Finally, Budesonide fully counteracted Dexamethasone- induced 22 
overexpression of the GR target genes Fkbp5 and Tfcp2l1 (Supplementary Fig. S2H). 23 
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Glucocorticoids, including Dexamethasone, are commonly used to induce collagens in cultured 1 
cells. Of note, we found that Budesonide but not Dexamethasone fully counteracted L-Pro -2 
dependent increase of Col1a and C-HyP (Fig. 2G-J; Supplementary Figure S2I).  3 
Together these findings supported the hypothesis that L-Pro -induced esMT depends on L-Pro -4 
mediated induction of collagen synthesis/hydroxylation, and indicated that Budesonide 5 
counteracts this effect (Fig. 2K).  6 
 7 
Genetic and pharmacological inhibition of collagen hydroxylation prevents esMT  8 
To directly test our hypothesis, and given that it is not feasible to knock-out all the members of 9 
the collagen family, we decided to interfere with collagen hydroxylation by targeting the Prolyl-10 
4-hydroxylases (P4Hs). P4H enzymes belong to the family of VitC/Fe+2/KG-dependent 11 
dioxygenases, and form tetrameric (α2:β2) complexes able to catalyze the hydroxylation of L-Pro 12 
residues in nascent collagens in the ER. Two out of the three genes coding for the alpha subunit 13 
of P4H, i.e. P4ha1 and 2, were expressed at similar levels in ESCs, whereas P4ha3 expression 14 
was nearly undetectable (Supplementary Fig. S3A). Of note, P4HA2 has been recently associated 15 
with collagen production and tumor progression of human breast cancer (23). We thus 16 
inactivated P4ha2 in ESCs by CRISPR/Cas9 and selected two independent clones (P4ha2KO #1 17 
and #2) that carry different genomic deletions at the boundary between exon 6 and intron 7, 18 
leading to a frame-shift and the formation of a premature stop codon (Fig. 3A; Supplementary 19 
Fig. S3B). Both P4ha2KO ESCs preserved the typical domed morphology, were highly AP 20 
positive (Fig. 3B), and retained the expression of key pluripotency markers (Supplementary Fig. 21 
S3C and S3D). To avoid the possibility that P4ha1 may, at least partially, compensate for the 22 
lack of P4ha2 we knocked down P4ha1 in P4ha2KO ESCs using two shRNAs, which target non-23 
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overlapping P4ha1 mRNA sequences (Fig. 3C; Supplementary Fig. S3E).  P4ha2KO/P4ha1KD 1 
ESCs retained AP activity and expression of pluripotency genes (Fig. 3B; Supplementary Fig. 2 
S3C and S3D). We then examined the effect of P4ha2KO and P4ha2KO/P4ha1KD on L-Pro-3 
induced esMT. Control ESCs (NT) retained high frequency of atypical colonies in response to L-4 
Pro, while P4ha2KO ESCs mostly developed typical domed colonies lacking the crown of 5 
mesenchymal-like cells scattered around the colony core (Fig. 3D). Remarkably, this phenotype 6 
was robustly enhanced in two independent P4ha2KO/P4ha1KD clones (Fig. 3D), indicating that 7 
P4ha1 partially compensates the lack of P4ha2. Consistent with the inhibitory effect on L-Pro-8 
induced phenotypic transition (domed-flat), cell motility was also impaired in P4H deficient 9 
ESCs (Supplementary Fig. S3F). Conversely, L-Pro-induced proliferation (Fig. 3E) or alleviation 10 
of AAR pathway (Supplementary Fig. S3G) was preserved, providing evidence that P4H activity 11 
is specifically required for L-Pro- induced esMT. Finally, as expected, C-Hyp accumulation was 12 
strongly reduced in P4H deficient ESCs (Fig. 3F). Together, these findings indicate that P4ha 13 
genetic ablation prevents collagen hydroxylation and antagonizes esMT mimicking the 14 
phenotypic and molecular effects of Budesonide, thus supporting the concept that esMT is 15 
functionally linked to collagen hydroxylation.  16 
 17 
Inhibition of collagen hydroxylation enhances VitC-dependent DNA and histone 18 
hydroxylation/demethylation in pluripotent stem cells 19 
Collagen hydroxylation requires VitC and our findings indicate that this crucial post-translational 20 
modification of collagen underpins L-Pro -induced esMT. However, exogenously added VitC 21 
antagonizes rather than induces esMT (Comes et al., 2013; Fig. 1C; Supplementary Fig. S1A) 22 
without blocking C-HyP accumulation (Fig. 2I and J). This apparent contradiction could be 23 
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reconciled by assuming the existence of a VitC-dependent mechanism that overcomes the 1 
agonistic effect of collagen hydroxylation on esMT (Fig. 2K). Of note, besides P4H, VitC is 2 
essential for the activity of different enzymes belonging to the family of Fe+2/KG-dependent 3 
dioxygenases with different substrate specificity, including DNA (TET) and Histones (JMJ), 4 
subcellular localization (cytoplasm, ER and nucleus), expression levels and kinetics parameters. 5 
Hence, we hypothesized that a sudden increase of collagen hydroxylation might channel VitC to 6 
the ER for the activity of collagen hydroxylases (P4Hs), concomitantly provoking its 7 
stoichiometric reduction in other cellular compartment, which translates into reduced activity of 8 
VitC-dependent dioxygenases, ultimately inducing esMT. Of note, we expect that such a 9 
substantial perturbation of VitC homeostasis might occur only in a VitC-limiting environment 10 
when collagen synthesis is induced. 11 
To test our hypothesis we asked whether a compartmentalized VitC-dependent reaction, i.e 12 
collagen hydroxylation in the ER, might impact on the activity of VitC/Fe+2/KG-dependent 13 
TET and JMJ dioxygenases and thus on DNA and histone methylation levels. We first compared 14 
the DNA methylation profiles of L-Pro- treated ESCs (6) and the Tet triple KO (TKO) ESCs (18) 15 
and found that 54% of the TET target regions were hypermethylated in L-Pro-treated cells at 16 
early time point (day 2), which increased up to 89% at day 5 (Fig. 3G). Prompted by these 17 
results, we evaluated the impact of P4h KO on the global levels of DNA hydroxymethylation 18 
(5hmC), which depends on the activity of TET enzymes. In a high-L-Pro/low-VitC condition, 19 
5hmC levels rapidly decreased in control but not in P4Hs deficient ESCs (Fig. 3 H and I; 20 
Supplementary Fig. S3H). Similarly, Budesonide counteracted the reduction of 5hmC in wild-21 
type ESCs (Supplementary Fig. S3I). We then evaluated the impact of P4h KO on JMJ 22 
dioxygenases, which target removal of H3K9/36 methylation and assessed whether VitC 23 
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supplementation blunted the effect of L-Pro. In a high-L-Pro/low-VitC environment the global 1 
levels of both H3K9me3 and H3K36me3 increased in Control but not in P4ha2KO and 2 
P4ha2
KO
/P4ha1
KD ESCs (Fig. 3J; Supplementary Fig. S3J). Notably, H3K9me3 levels were 3 
even lower in the P4ha2KO/P4ha1KD double mutant compared to P4ha2KO (Fig. 3J), consistent 4 
with the idea that VitC availability may progressively increase in the nucleus as C-Hyp levels 5 
decrease in the ER (Fig. 3F). In keeping with the idea that VitC is a limiting metabolite in ESCs 6 
(12), its addition not only prevented L-Pro- dependent increase of H3K9me3 levels but also 7 
further reduced H3K9me3 global levels in a low L-Pro environment (Fig. 3K). Furthermore, 8 
Budesonide mimicked the antagonistic effect of VitC, preventing both L-Pro -dependent esMT 9 
(Fig. 1 C and H; Fig. 2A; Supplementary Fig. S1A) and increase of H3K9me3 levels 10 
(Supplementary Fig. S3K). Of note, neither L-Pro, nor Budesonide modified the expression of the 11 
specific DNA/histone demethylases, including Tet1, 2, 3 and Jmjd2c (H3K9me2/me3 and 12 
H3K36me2/me3 demethylation; Supplementary Fig. S3L) ruling out the possibility the observed 13 
epigenetic changes reflects altered expression of the enzymes.  14 
Collectively, these findings indicate that increased collagen hydroxylation causes DNA and 15 
histones methylation, and suggest that this occurs by altering VitC homeostasis and reducing the 16 
activity of nuclear dioxygenases (Fig. 3L). Budesonide and P4H deficiency interferes with this 17 
metabolic perturbation by reducing collagen hydroxylation with different mechanisms. 18 
Specifically, Budesonide blocks collagen synthesis at RNA and protein levels, and as a 19 
consequence reduces collagen hydroxylation; whereas, P4H deficiency directly interferes with 20 
hydroxylation of nascent collagens within the ER.  21 
Collagen hydroxylation influences the epigenetic landscape of tumor cells and induces cell 22 
state transition  23 
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The above results raise the possibility that this mechanism might be general applicable to 1 
mesenchymal transition processes and critically important in pathological situations, such as 2 
cancer progression and metastatic dissemination. Consistent with the inhibitory effects on L-Pro -3 
induced esMT in ESCs, Budesonide robustly inhibited human lung cancer A549 cell migration in 4 
vitro, in tumor spheroid and Boyden chambers assays (Fig. 4 A and B; Supplementary Fig. S4A-5 
C), without affecting cell proliferation (Supplementary Fig. S4D). Furthermore, similar to what 6 
observed in pluripotent stem cells, Budesonide reduced collagen accumulation in A549 at RNA 7 
and protein level (Fig. 4C; Supplementary Fig. S4E). We thus went on and assessed the effect of 8 
Budesonide on histone methylation, by analyzing the global levels of different methylation 9 
marks including H3K9me2/me3, H3K36me3, H3K27me3 and H3K4me3, which are the known 10 
substrates of the dioxygenases involved in histone demethylation. Remarkably, Budesonide 11 
significantly reduced global histone methylation in A549 cells (Fig. 4D) suggesting that an 12 
antagonistic interplay between collagen and histone hydroxylation occurs in cancer cells. To get 13 
further mechanistic insights into this phenomenon, we knocked down P4HA2 in A549 14 
(Supplementary Fig. S4F-G) and confirmed that C-Hyp accumulation was strongly reduced 15 
compared to NT control cells (Fig. 4E). Consistent with what observed in ESCs, P4HA2KD 16 
strongly reduced A549 cell migration (Fig. 4F; Supplementary Fig. S4H) but not proliferation 17 
(Supplementary Fig. S4I), and significantly reduced histone methylation (Fig. 4G). 18 
Prompted by these results and to validate the model in a different tumor type, we focused on 19 
breast cancer. Interestingly, elevated expression of P4HA2 has been recently associated with 20 
poor prognosis in a variety of breast cancers (24). We first extended and corroborated the latter 21 
observations by analyzing P4HA2 expression levels in an independent Breast Cancer dataset, 22 
encompassing nearly 2000 patients with complete clinical-pathological follow up. We found that 23 
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elevated level of P4HA2 is significantly associated with decrease survival, and, more relevantly, 1 
is an independent predictor of disease outcome with respect to a set of standard 2 
clinicopathological parameters in multivariate analysis (Fig. 5A). 3 
To further explore this mechanism, we investigated the effect of P4HA2KD on the triple negative 4 
breast cancer (TNBC) cell line SUM159, which are characterized by a high degree of 5 
heterogeneity/plasticity and recapitulates the key features of collective invasion typical of human 6 
breast cancers (25). Interestingly, we found that interfering with P4HA2 expression (Fig. 5B) 7 
converted SUM159 cells to a more epithelial-like state (Fig. 5 C and D), without affecting cell 8 
proliferation (Fig. 5E), and reduces C-Hyp levels (Fig. 5F). Of note, P4HA2KD reduced the 9 
global levels of different methylation marks including H3K27me3, H3K36me3, H3K4me3, 10 
H3K9me2/me3 and (Fig. 5G). To investigate this phenotype further, we assessed the effect of 11 
Budesonide and first confirmed that it reduced Col1a1 and C-HyP accumulation in SUM159 12 
cells (Fig. 6 A and B). Remarkably, Budesonide treatment concomitantly led to reduction of 13 
H3K9me2/3, H3K36me3 and H3K27me3 but not H3K4me3 levels (Fig. 6C). Of note, 14 
expression of the specific dioxygenases involved in histone demethylation, including JMJD3 15 
(H3K27me3), JMJD2A (H3K9me2/me3 and H3K36me2/me3) and JARID1A (H3K4me3) was 16 
not affected (Supplementary Fig. S5A), thus further supporting the idea that the global reduction 17 
of histone methylation was due to increased activity rather than expression of these enzymes. 18 
Complementary to these findings, we showed that VitC supplementation significantly reduced 19 
H3K9me2/3, H3K27me3 and H3K4me3 in a dose- and histone mark- dependent manner (Fig. 20 
6D), indicating that VitC is a limiting factor for proper function of JMJ demethylases in 21 
SUM159 cells, and further supporting the idea that variations in the levels and/or 22 
compartmentalization of VitC impacts on the activity of nuclear dioxygenases in cancer cells.  23 
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All together these findings indicate that collagen synthesis/hydroxylation underpins cell state 1 
transition dynamics, and influences the epigenetic status of normal and tumor cells. 2 
 3 
Budesonide blocks metastatic dissemination of TNBC cells by preventing collagen 4 
deposition and mesenchymal transition 5 
Prompted by these results and the potential therapeutic relevance of targeting mesenchymal 6 
transition as a strategy to prevent tumor cell dissemination, we further investigated the effect of 7 
Budesonide on SUM159 cells. First, we tested the impact of Budesonide on SUM159 cell 8 
invasion using a 3D organotypic culture (Fig. 7A). Treatment with Budesonide robustly reduced 9 
the collective invasive ability of SUM159 spheroids and significantly increased colony 10 
compaction and circularity in a dose dependent fashion (Fig. 7B; Supplementary Fig. S5B), 11 
without affecting cell proliferation (Supplementary Fig. S5C). We further corroborated these in 12 
vitro findings using an experimental metastatic murine model. To this end, we orthotopically 13 
injected luciferase-expressing SUM159 cells into the mammary fat pad of immunocompromised 14 
mice. Budesonide treatment altered significantly the cell shape and stromal collagenolytic 15 
organization of primary tumors, which were composed of cuboidal, epitheliod cells with a 16 
reduced and less organized collagen-surrounding matrix (Fig. 7C and D). On the contrary, in 17 
control animal primary tumors were primarily composed of elongated, spindle shaped cells 18 
surrounded by a thick collagenous stromal desmoplastic reaction (Fig. 7C and D). Consistently, 19 
Budesonide treatment reduced primary tumors volume (Supplementary Fig. S5D and E), but had 20 
no effect on the number of KI67 and Caspase positive cells (Supplementary Fig. S5F). 21 
Remarkably, instead, it completely abrogated the development of metastatic foci into the lung 22 
(Fig. 7 E and F). Collectively, these findings indicate that Budesonide-mediated interference 23 
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with collagen production/deposition hampers mesenchymal transition state, ultimately impairing 1 
metastatic dissemination.  2 
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Discussion 1 
Collagen hydroxylation and DNA/histone hydroxylation/demethylation are catalyzed by 2 
dioxygenases superfamily enzymes, namely the prolyl 4-hydroxylases (P4Hs) in the endoplasmic 3 
reticulum (ER), and Ten-Eleven Translocation (TET) and Jumonji (JMJ) demethylases in the 4 
nucleus, respectively. Here, we demonstrate that collagen and DNA/histone hydroxylation show 5 
an antagonistic interplay. Mechanistically, we propose that this previously unexplored interplay 6 
relies on the availability VitC, which is an essential cofactor for the activity of both P4Hs and 7 
TET/JMJ. This idea is in line with emerging evidence that reduced availability of dioxygenases 8 
substrates/cofactors, such as O2 and VitC, promotes cell state transition and metastatic 9 
dissemination by reducing the activity of TET and JMJ demethylases with a concomitant 10 
increase of DNA and histone methylation (26, 27). Here we propose that collagen prolyl 11 
hydroxylation is a previously unexplored key component of this mechanism. Several lines of 12 
evidence support our model. First, genome wide analyses in embryonic stem cells (ESCs) reveal 13 
that a large fraction of TET1-3 target DNA regions are methylated after exposure to a high L-Pro 14 
regimen, which results in increased collagen synthesis/hydroxylation. Second, increased collagen 15 
synthesis/hydroxylation under VitC limiting conditions rapidly reduces 5hmC and increases 16 
H3K9/K36 histone methylation, which is in agreement with a reduced activity of TET and JMJ, 17 
respectively. Finally, interfering with collagen synthesis/hydroxylation, by either 18 
pharmacological treatment with the glucocorticoid Budesonide (collagen synthesis) or genetic 19 
ablation of P4HA2 (collagen hydroxylation), blocks cell state transition in pluripotent stem cells 20 
and tumor cells.  21 
Of note, the latter findings are highly relevant for cancer biology as high P4HA2 expression is a 22 
poor prognostic marker in breast cancer patients and correlates with the metastatic progression of 23 
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triple negative breast cancer (TNBC) cells (24) and our findings). Accordingly, we demonstrate 1 
that P4HA2 knockdown reduces global H3K9, H3K36, H3K4 and H3K27 methylation levels and 2 
reverts the mesenchymal phenotype of TNBC SUM159 cells to a more epithelial-like phenotype. 3 
Of note, the TNBC SUM159 cells are highly heterogeneous and can be sorted into low and high 4 
tumor-initiating populations based on the expression of the basal epithelial marker integrin-β4 5 
(ITGB) (28). Interestingly, we noticed that P4HA2 expression is significantly higher in the fully 6 
mesenchymal ITGBlow subpopulation vs the ITGB4high subpopulation that show hybrid 7 
epithelial/mesenchymal phenotype (28). Although further studies are necessary, we speculate 8 
that this collagen hydroxylation/P4HA2 -dependent remodeling of the epigenetic landscape may 9 
underlie, at least in part, the molecular and functional heterogeneity of TNBC cells. 10 
In line with our idea, pharmacological targeting of this collagen-epigenetic axis with 11 
Budesonide, identified in this study, inhibits the metastatic dissemination of SUM159 cells by 12 
preventing mesenchymal-transition. Interestingly, Budesonide, has been very recently identified 13 
in a combined connectivity mapping and pharmacoepidemiological approach as a drug with 14 
potential breast cancer-preventing properties (29). Moreover, Budesonide is universally 15 
employed to treat asthma, and asthma was recently associated with reduced risk of developing 16 
pancreatic ductal adenocarcinoma (PDAC) (30). Furthermore, Budesonide is also used to treat 17 
the collagenous colitis, a rare inflammatory disorder associated with collagen accumulation in 18 
the colorectal mucosa (31, 32), and its therapeutic efficacy is ascribed to the anti-inflammatory 19 
activity of GCs (33). Thus, our unexpected findings that Budesonide blocks mesenchymal 20 
transition interfering with collagen accumulation provide novel insights into its therapeutic 21 
effects. Of note, the mechanism behind the effects of Budesonide remains to be fully clarified. 22 
Indeed, although our findings raised the possibility of potential involvement of the GR, the 23 
on May 18, 2019. © 2019 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on May 6, 2019; DOI: 10.1158/0008-5472.CAN-18-2070 
 27 
mechanism may prove more complex and its complete elucidation will require further 1 
investigations. Specifically, we cannot rule out the possibility that off-target effects of 2 
Budesonide at the concentration used, including for instance inhibition of P4H activity, could be 3 
responsible of the observed phenotypes. 4 
Epigenetic mechanisms may govern the accumulation of collagen by reducing promoter 5 
methylation and increasing expression of collagen genes (34, 35). Disruption of this epigenetic-6 
>collagen axis is considered as the main cause of the deregulation of collagen deposition during 7 
aging and in pathological conditions, including tumorigenesis (36). Here we reveal the existence 8 
of a reverse collagen->epigenetic functional axis associated with cell state transition in normal 9 
and pathological conditions.  10 
In conclusion, our findings provide evidence of a previously unexplored functional interplay 11 
between collagen and DNA/Histone hydroxylation and identify P4HA2 as a key component of 12 
this mechanism. Interestingly, it has been recently reported that expression of another member of 13 
P4H family, P4ha1, reduces prolyl-hydroxylation of HIF-1α by modulating the levels of 14 
ketoglutarate (KG) and succinate in the cytoplasm (37). Of note, hydroxylation of HIF-1α is 15 
catalyzed by the Prolyl hydroxylases (PHDs), which are VitC-dependent dioxygenase belonging 16 
to the same family of TET and JMJ. The evidences from this paper of a collagen hydroxylation 17 
(ER) -> HIF hydroxylation (cytoplasm) axis strongly support our findings and can be well 18 
explained with the model proposed herein. 19 
Finally, we identify Budesonide as a potent inhibitor of this mechanism and a novel drug 20 
candidate for the treatment of a broad spectrum of diseases in which cell fate transition and 21 
fibrosis are involved, including metastatic cancer. 22 
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Figure Legends 1 
Figure 1. HTS-based identification of drugs that block esMT. (A) Photomicrographs of colony 2 
types. (B) Miniaturization of the colony phenotype-based drug-screening method. (C) Colony 3 
type quantification (domed vs flat) of ESCs treated with L-Pro (250µM) ± VitC (150µM) or 4 
CHIR99021 (CHIR, 3µM) or left untreated (day5). Data are mean±SD (*p≤0.001; ~100 colonies 5 
scored/condition n=5). (D) Representative pictures of the screening results. Red and green circles 6 
indicate ESC inhibitors (no colonies) and esMT inhibitors (domed-shaped colonies), 7 
respectively. (E) Enrichment of ESC inhibitors in specific therapeutic classes (Z-score test, 8 
p<0.0001). (F) Molecular target(s) of ESC inhibitors from PubChem/PubMed databases. (G) 9 
Structure-activity relationship of drugs belonging to the Ca2+-channel blockers 1,4-10 
dihydropyridines. (H) Colony type quantification of ESCs treated ± L-Pro ± esMT inhibitors 11 
(day5). DMSO was used as control. VitC and CHIR99021 were used as positive controls. Data 12 
are meanSD (*p≤0.001; ~100 colonies scored/condition n=5). 13 
 14 
Figure 2. Molecular and functional characterization of esMT inhibitors. (A-C) Effect of 15 
Budesonide, Spiramycin, Propafenone on L-Pro -induced cell motility (A), down-regulation of 16 
AAR markers (B) and cell proliferation (C). DMSO is used as control. Representative frames of 17 
time-lapse series from untreated (-L-Pro) and L-Pro ± esMTi treated ESCs. Images were captured 18 
from day 3 to 4 post plating (A). qPCR analysis of Atf4, Trb3 and Nupr1 expression. Data are 19 
fold change vs untreated after normalization to Gapdh and are mean±SEM (*p≤0.01; n=3) (B). 20 
FACS analysis of EdU incorporation. Data are shown as fold change vs untreated and are 21 
mean±SEM (*p≤0.01; n=3) (C). (D) Effect of Budesonide, Spiramycin, Propafenone on the 22 
reversed mesenchymal-like to embryonic stem cell transition (MesT). Freshly generated L-Pro-23 
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treated ESCs (mesenchymal-like flat colonies) were plated with L-Pro ± the indicated compounds 1 
and analyzed at day 5. Colony type quantification (domed vs flat; left). Data are mean±SD 2 
(*p≤0.01; ~100 colonies scored/condition; n=3). Representative pictures of L-Pro ± esMTi or 3 
VitC -treated ESCs (middle). Effect of L-Pro, VitC and Budesonide on esMT and MesT (right). 4 
(E) Western blot analysis of Col1a1 (top) and Collagen Hydroxyproline (C-HyP; bottom) in 5 
ESCs ± L-Pro (1mM). Densitometric analysis (ADU) is shown as fold change vs untreated ESCs. 6 
Data are mean±SEM (*p≤0.01; n=3) after normalization to Gapdh. (F) Confocal images of C-7 
HyP (red) and Protein disulphide isomerase (PDI; green) immunofluorescence on ESCs ± L-Pro 8 
(left). Half circles indicate Endoplasmic reticulum (ER). Quantification of C-HyP intensity 9 
(right). Data are mean±SD (*p≤0.001; n=3). (G) Western blot analysis of Col1a1 in ESCs + L-10 
Pro (1mM) ± Budesonide (10μM). Densitometric analysis (ADU) is shown as fold change vs 11 
ESCs + L-Pro. Data are mean±SEM (*p≤0.01; n=3) after normalization to Gapdh. (H) 12 
Fluorescence photomicrographs of Col1a1 (green) and confocal images of C-HyP (red) 13 
immunofluorescence on L-Pro-treated cells ± Budesonide. Nuclei are stained with DAPI. (I-J) 14 
Western blot analysis of C-HyP in ESCs (I) and PiCs (J) treated with L-Pro (1mM) ± 15 
Budesonide (10µM) or VitC (500µM). ADU is shown as C-HyP/Gapdh. Data are mean±SEM 16 
(*p≤0.01; n=3). (K) Schematic representation of L-Pro, VitC and Budesonide effects on C-HyP. 17 
 18 
Figure 3. Generation and functional characterization of P4ha2KO and P4ha2KO/a1KD ESCs. (A) 19 
RT-PCR of P4ha2 from CRISPR-Cas9 Non Targeting (NT) and P4ha2KO ESCs. (B) 20 
Representative pictures of Alkaline phosphatase (AP) staining of NT, P4ha2KO and 21 
P4ha2
KO
/a1
KD ESC colonies. (C) Western blot analysis of P4ha1 levels in Control (NT), 22 
P4ha2
KO
/a1
KD and P4ha2KO ESCs. Anti-Gapdh antibody was used as loading control. (D) 23 
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Representative photomicrographs (left) and colony type quantification (right) of colonies 1 
generated from NT, P4ha2KO and P4ha2KO/a1KD ESCs ± L-Pro (500µM) at day 5. Data are 2 
mean±SD (*p<0.01, ~100 colonies scored/condition; n=5). (E) L-Pro -induced proliferation of 3 
NT, P4ha2KO and P4ha2KO/a1KD ESCs ± L-Pro (500µM) analyzed by CCK-8 assay. Data are 4 
shown as fold change vs NT minus L-Pro. Data are mean±SEM (*p<0.01; n=3). (F) Confocal 5 
images of C-HyP immunofluorescence on NT, P4ha2KO and P4ha2KO/a1KD ESCs treated with L-6 
Pro (500µM) (top). Nuclei are stained with DAPI. C-Hyp intensity quantification (bottom). Data 7 
are mean±SD (*p≤0.01; n=3). (G) Pie graphs comparing the DNA methylation profiles of L-Pro- 8 
treated ESCs and the Tet triple KO (TKO) ESCs. Blue slices indicate the percentage of hyper-9 
DMRs in TKO that are hypermethylated by L-Pro at day 2 (top) and day 5 (bottom); p-value<10-10 
16. (H-I) ELISA-based quantification (H) and immunofluorescence (I) of 5hmC in Control (NT), 11 
P4ha2
KO and P4ha2KO/a1KD ESCs ± L-Pro (500 µM; 24 hrs). (H) 5hmC levels are shown as fold 12 
change vs NT minus L-Pro. Data are mean±SEM (*p≤0.01; n=3). (I) Fluorescence 13 
photomicrographs of 5hmC (red). Nuclei are stained with DAPI. (J-K) Western blot analysis of 14 
H3K9me3 in NT, P4ha2KO and P4ha2KO/a1KD ESCs ± L-Pro (500µM) (J), and in wild-type ESCs 15 
± L-Pro (500µM) ± VitC (K). ADU is shown as fold change vs untreated (minus L-Pro) Controls 16 
after normalization to total histone H3. Data are mean±SEM (*p≤0.01; n=3). (L) Schematic 17 
representation of VitC-dependent collagen hydroxylation (P4H) and DNA/Histone hydroxylation 18 
(TET/JMJ) in the different subcellular compartments. 19 
 20 
Figure 4. Collagen synthesis/hydroxylation induces mesenchymal transition in lung epithelial 21 
tumor cells (A549) modifying the epigenetic landscape. (A) Schematic representation of 2D cell 22 
migration assay from A549 lung tumor spheroid. (B) Representative photomicrographs of crystal 23 
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violet stained A549 spheroids treated with Budesonide (10 and 20 µM) or vehicle (DMSO). (C) 1 
Representative pictures of Col1a1 immunofluorescence on A549 cells treated with Budesonide 2 
(10µM) or DMSO for 48 hrs. Nuclei are stained with DAPI. (D) Western blot analysis of 3 
H3K9me2/me3, H3K27me3, H3K36me3 and H3K4me3 in wild-type A549 cells treated with 4 
Budesonide (10 and 20µM) or DMSO as control, for 48 hrs. ADU is shown as fold change vs 5 
DMSO after normalization to total histone H3. Data are mean±SEM (*p≤0.01; n=3). (E-G) 6 
Generation and functional characterization of P4HA2KD A549 cells. (E) Confocal images of C-7 
HyP immunofluorescence on NT and P4HA2KD A549 cells (top). Nuclei are stained with DAPI. 8 
C-Hyp intensity quantification (bottom). Data are mean±SE (*p≤0.01; n=2). (F) Representative 9 
photomicrographs of NT and P4HA2KD A549 derived spheroids stained with crystal violet (top). 10 
Quantification of spreading spheroids (bottom). Data are mean±SE (*p≤0.01; n=3). (G) Western 11 
blot analysis of H3K9me2 and H3K36me3 in NT and P4HA2KD A549 cells. ADU is shown as 12 
fold change vs NT after normalization to total histone H3. Data are mean±SEM (*p≤0.01; n=3).  13 
 14 
Figure 5. Collagen prolyl hydroxylation influences the mesenchymal phenotype of triple-15 
negative breast cancer (TNBC) cells modifying the epigenetic landscape. (A) P4HA2 expression 16 
is an independent predictor of poor prognosis in Breast Cancer. Left panel: prognostic 17 
significance of P4HA2 expression determined by Kaplan-Meier survival analysis in the 18 
METABRIC datasets. Right panels: The risk ratios (High vs. Low P4HA2 expression) were 19 
estimated with a Cox proportional hazards in univariate and multivariable model, adjusted for 20 
standard clinicopathological parameters. (B) Western blot analysis of P4HA2 in Control non-21 
targeted (NT) and P4HA2KD SUM159 cells. Anti-GAPDH antibody was used as loading control. 22 
(C) Representative pictures of NT and P4HA2KD SUM159 cell morphology. (D) Western blot 23 
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analysis of FIBRONECTIN1 (FB1) and VIMENTIN levels in NT and P4HA2KD SUM159 cells. 1 
Anti-GAPDH antibody was used as loading control. (E) CCK-8 based proliferation assay of NT 2 
and P4HA2KD SUM159 cells. Data are shown as fold change vs NT and are mean±SEM (n=3). 3 
(F) Confocal images of C-HyP immunofluorescence (left) and C-Hyp intensity quantification 4 
(right) of NT and P4HA2KD SUM159 cells. Nuclei are stained with DAPI. Data are mean±SE 5 
(*p≤0.01; n=2). (G) Western blot analysis of H3K27me3, H3K36me3, H3K4me3 and 6 
H3K9me2/me3 in NT and P4HA2KD SUM159 cells. ADU is shown as fold change vs NT after 7 
normalization to total histone H3. Data are mean±SEM (*p≤0.01; n=3). 8 
 9 
Figure 6. (A-B) Confocal images of Col1a1 (A) and C-HyP (B) immunofluorescence and signal 10 
intensity quantification of wild-type SUM159 cells ± Budesonide (25 μM) for 48 hrs. Nuclei are 11 
stained with DAPI. Data are mean±SE (*p≤0.01; n=3). (C) Western blot analysis of 12 
H3K9me2/me3, H3K36me3, and H3K27me3 and H3K4me3 in SUM159 cells ± Budesonide (25 13 
μM) for 48 hrs. ADU is shown as fold change vs DMSO after normalization to total histone H3. 14 
Data are mean ± SEM (*p≤0.01; n=3). (D) Western blot analysis of H3K9me2/me3, H3K27me3, 15 
H3K4me3 and H3K36me3 in SUM159 cells ± VitC (10, 20 and 50 μM). ADU is shown as fold 16 
change vs untreated cells after normalization to total histone H3. Data are mean±SEM (*p≤0.01; 17 
n=3). 18 
 19 
Figure 7. Budesonide blocks triple-negative breast cancer cell migration and invasion in vitro 20 
and in vivo (A) Schematic representation of SUM-159 3D organotypic culture assay. (B) 21 
Representative pictures (left) and circularity index (right) of SUM-159-derived spheroids ± 22 
Budesonide. The colony circularity was measured by using the formula {4π*area/perimeter^2}. 23 
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A value of 1.0 indicates a perfect circle. As the value approaches to 0.0, it indicates an 1 
increasingly elongated shape. Data are mean±SD (*p≤0.01; 50 colonies/group; n=3). (C) 2 
Representative pictures of H&E and VIMENTIN staining on sections from SUM-159 3 
Luciferase-derived tumors (left). Cell circularity (right) is shown as mean±SD (*p≤0.01; 50 4 
cells/tumors, n=5 mice/group). (D) Representative pictures of Picrosirius red staining and 5 
polarized light microscopy of tumor sections (left). Collagen quantification is shown as 6 
percentage of collagen area/field (right). Data are mean±SD (*p≤0.01; n=30 fields/group). (E) 7 
Dissemination to lung and distal lymph nodes by in vivo imaging in mice ± Budesonide (top). A 8 
dark screen was placed on top of the primary tumor to visualize the lower signal of distal foci. 9 
The Relative Luciferase counts/mouse (bottom) are shown as mean±SD (*p<0.01; n=5 10 
mice/group). (F) Representative pictures of Human Nuclei staining on lung sections from mice ± 11 
Budesonide (left). Quantification of disseminated tumor cells is shown as number of 12 
micrometastasis/lung (right). Data are the mean±SD (*p<0.01; n=5 mice/group). 13 
 14 
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